BHVN – biohaven pharmaceutical holding company ltd. common shares (US:NASDAQ)

News

Biohaven (NYSE:BHVN) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity [Seeking Alpha]
Biohaven (NYSE:BHVN) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.
Biohaven CEO Dr. Vlad Coric goes one-on-one with Jim Cramer [CNBC]
Biohaven CEO Dr. Vlad Corcic goes one-on-one with Jim Cramer [CNBC]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com